At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $231.09M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 3.38: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.54BCNY231.09M · vs all stocks (USD)
Trailing P/E
137.67xRevenue (TTM)
548.40MCNY82.21M · vs all stocks (USD)
Profit Margin
1.85%Beta
0.1190xvs all stocks
52-Week Change
-45.37%vs all stocks
Market Capitalization
1.54BCNY231.09M · vs all stocks (USD)
Enterprise Value
1.22BCNY183.38M · vs all stocks (USD)
Trailing P/E
137.67xPrice to Sales (TTM)
2.81xPrice to Book (MRQ)
0.9241xEnterprise to Revenue
2.23xEnterprise to EBITDA
63.21xGross Margin
74.02%Profit Margin
1.85%Operating Margin
-5.46%Return on Assets (TTM)
0.09%Return on Equity (TTM)
0.63%Revenue (TTM)
548.40MCNY82.21M · vs all stocks (USD)
Revenue per Share (TTM)
1.54CNYUpdated Oct 22, 2026Quarterly Revenue Growth
-11.40%Gross Profit (TTM)
421.26MCNY63.15M · vs all stocks (USD)
EBITDA (TTM)
49.45MCNY7.41M · vs all stocks (USD)
Net Income (TTM)
10.17MCNY1.52M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-11.39%Operating Cash Flow (TTM)
41.32MCNY6.19M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
75.84MCNY11.37M · vs all stocks (USD)
5-Year Average Dividend Yield
0.58%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-1.26MCNYFY2025 · Dec 31, 2025Revenue
544.04MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
125.12MCNYFY2025 · Dec 31, 2025Gross Profit
418.92MCNYFY2025 · Dec 31, 2025Operating Income
5.32MCNY797.35K · vs all stocks (USD)
Pre-tax Income
18.57MCNYFY2025 · Dec 31, 2025Income Tax Expense
3.24MCNYFY2025 · Dec 31, 2025Net Income
15.33MCNYFY2025 · Dec 31, 2025EBIT
23.37MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
49.45MCNYFY2025 · Dec 31, 2025Research & Development
30.81MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
317.81MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.35MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.72MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
4.80MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0442CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0442CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
352.41MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
352.41MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
15.33MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
244.96KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
595.07KCNYFY2025 · Dec 31, 2025Free Cash Flow
-124.18MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
310.79MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
15.33MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.62MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-17.76MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.40MCNYFY2025 · Dec 31, 2025Capital Expenditures
-124.78MCNYFY2025 · Dec 31, 2025Net Acquisitions
139.02MCNYFY2025 · Dec 31, 2025Purchase of Investments
-212.80KCNYFY2025 · Dec 31, 2025Sale of Investments
13.01MCNYFY2025 · Dec 31, 2025Other Investing Activity
-23.06MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
3.97MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
890.10MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-924.62MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-13.47MCNYFY2025 · Dec 31, 2025Other Financing Charges
-7.88MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-55.87MCNYFY2025 · Dec 31, 2025Shares Outstanding
373.27MSharesUpdated Oct 22, 2026Float Shares
230.39MSharesUpdated Oct 22, 2026% Held by Insiders
34.30%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
318.11MCNY47.68M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.8920CNYUpdated Oct 22, 2026Total Debt (MRQ)
70.64MCNY10.59M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0444xCurrent Ratio (MRQ)
1.80xBook Value per Share (MRQ)
4.47CNYUpdated Oct 22, 2026Total Assets
1.93BCNY289.00M · vs all stocks (USD)
Total Current Assets
621.18MCNYFY2025 · Dec 31, 2025Total Liabilities
369.61MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.31BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
43.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
326.47MCNYFY2025 · Dec 31, 2025Cash
296.40MCNYFY2025 · Dec 31, 2025Cash Equivalents
14.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
310.79MCNYFY2025 · Dec 31, 2025Other Short-term Investments
49.28MCNYFY2025 · Dec 31, 2025Accounts Receivable
115.91MCNYFY2025 · Dec 31, 2025Inventory
32.81MCNYFY2025 · Dec 31, 2025Accounts Payable
8.89MCNYFY2025 · Dec 31, 2025Short-term Debt
20.63MCNYFY2025 · Dec 31, 2025Other Current Liabilities
4.59MCNYFY2025 · Dec 31, 2025Long-term Debt
3.39MCNYFY2025 · Dec 31, 2025Common Stock (Book)
373.27MCNYFY2025 · Dec 31, 2025Retained Earnings
515.28MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.56BCNY233.60M · vs all stocks (USD)
Treasury Stock
149.50MCNYFY2025 · Dec 31, 202552-Week Low
4.13CNYUpdated Oct 22, 202652-Week High
9.35CNYUpdated Oct 22, 202652-Week Change
-45.37%vs all stocks
Beta
0.1190xvs all stocks
50-Day MA
4.70CNYUpdated Oct 22, 2026200-Day MA
6.29CNYUpdated Oct 22, 2026Avg 10-Day Volume
2.30MSharesUpdated Oct 22, 2026Avg 30-Day Volume
2.38MSharesUpdated Oct 22, 2026Diluted EPS (TTM)
0.0300CNYUpdated Oct 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.74Profit Margin: 0.02
Financial Health
Altman Z-Score 3.38: safe zoneNotable
Altman Z-Score: 3.38
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $231.09M, lower than 95% of all stocks globallySignificant
Market cap (USD): 231,086,780.922Global P5: 273,689,256.68
Companies that share the same coordination system — how they create, deliver, or capture value.
Curocell Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
BioAge Labs, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eubiologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Keros Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule